Dissection of aberrant GPCR signaling in tumorigenesis - A systems biology approach

Cancer Genomics and Proteomics

Volumn 9, Issue 1, 2012, Pages 37-50

  Wu, Jinhua ^a   Xie, Na ^a   Zhao, Xia ^a   Nice, Edouard C ^b   Huang, Canhua ^a  

^a SICHUAN UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Cell signaling; Drug discovery; GPCR; Review; Systems biology; Tumorigenesis

Indexed keywords

ADENOSINE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR7; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; INTERLEUKIN 8; MELANOCORTIN; MELATONIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROPEPTIDE; RHODOPSIN; SPHINGOSINE 1 PHOSPHATE; THROMBIN;

AMINO TERMINAL SEQUENCE; BASAL CELL CARCINOMA; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ADHESION; CELL MEMBRANE; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; EXPRESSED SEQUENCE TAG; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

MAMMALIA;

EID: 84855372404     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Marinissen MJ and Gutkind JS: G-Protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22: 368-376, 2001. (Pubitemid 32592476)
2. Alkhalfioui F, Magnin T and Wagner R: From purified GPCRs to drug discovery: the promise of protein-based methodologies. Curr Opin Pharmacol 9: 629-635, 2009.
3. Lefkowitz RJ: The superfamily of heptahelical receptors. Nat Cell Biol 2: E133-136, 2000.
4. Schoneberg T, Schulz A, Biebermann H, Hermsdorf T, Rompier H and Sangkuhl K: Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 104: 173-206, 2004. (Pubitemid 39531926)
5. Lattin J, Zidar DA, Schroder K, Kellie S, Hume DA and Sweet MJ: G-Protein-coupled receptor expression, function, and signaling in macrophages. J Leukoc Biol 82: 16-32, 2007. (Pubitemid 47026413)
6. Eo HS, Choi JP, Noh SJ, Hur CG and Kim W: A combined approach for the classification of G-protein-coupled receptors and its application to detect GPCR splice variants. Comput Biol Chem 31: 246-256, 2007. (Pubitemid 47089109)
7. Devi LA: Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 22: 532-537, 2001.
8. Fredriksson R, Lagerstrom MC, Lundin LG and Schioth HB: The G-protein-coupled receptors in the human genome form five main families. Phylogenese analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272, 2003. (Pubitemid 36627220)
9. Kolakowski LF Jr.: GCRDb: a G-protein-coupled receptor database. Receptors Channels 2: 1-7, 1994.
10. Bockaert J and Pin JP: Molecular tinkering of G-Protein-coupled receptors: an evolutionary success. EMBO J 18: 1723-1729, 1999. (Pubitemid 29158516)
11. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M and Harmar AJ: International Union of Pharmacology. XLVI. G-Protein-coupled receptor list. Pharmacol Rev 57: 279-288, 2005. (Pubitemid 41043887)
12. Davies MN, Seeker A, Halling-Brown M, Moss DS, Freitas AA, Timmis J, Clark E and Flower DR: GPCRTree: online hierarchical classification of GPCR function. BMC Res Notes 1: 67, 2008.
13. Edwards SW, Tan CM and Limbird LE: Localization of G-protein-coupled receptors in health and disease. Trends Pharmacol Sci 21: 304-308, 2000. (Pubitemid 30642920)
14. Pierce KL, Premont RT and Lefkowitz RJ: Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639-650, 2002. (Pubitemid 34987785)
15. Lee HJ, Wall B and Chen S: G-Protein-coupled receptors and melanoma. Pigment Cell Melanoma Res 21: 415-428, 2008. (Pubitemid 351990969)
16. Flower DR: Modelling G-Protein-coupled receptors for drug design. Biochim Biophys Acta 1422: 207-234, 1999.
17. Schoneberg T, Hofreiter M, Schulz A and Rompler H: Learning from the past: evolution of GPCR functions. Trends Pharmacol Sci 28: 117-121, 2007. (Pubitemid 46283586)
18. Zhu T, Fang LY and Xie X: Development of a universal high-throughput calcium assay for G-Protein-coupled receptors with promiscuous G-protein G alpha15/16. Acta Pharmacol Sin 29: 507-516, 2008. (Pubitemid 351465513)
19. Williams C and Hill SJ: GPCR signaling: understanding the pathway to successful drug discovery. Methods Mol Biol 552: 39-50, 2009.
20. Heitzler D, Crepieux P, Poupon A, Clement F, Fages F and Reiter E: Towards a systems biology approach of G-protein-coupled receptor signalling: challenges and expectations. C R Biol 332: 947-957, 2009.
21. Parmigiani RB, Magalhaes GS, Galante PA, Manzini CV, Camargo AA and Malnic B: A novel human G-protein-coupled receptor is overexpressed in prostate cancer. Genet Mol Res 3: 521-531, 2004. (Pubitemid 40318046)
22. Daaka Y: G Proteins in cancer: the prostate cancer paradigm. Sci STKE 2004: re2, 2004.
23. Gutkind JS: Regulation of mitogen-activated protein kinase signaling networks by G-protein-coupled receptors. Sci STKE 2000: re1, 2000.
24. Karnik SS, Gogonea C, Patil S, Saad Y and Takezako T: Activation of G-Protein-coupled receptors: a common molecular mechanism. Trends Endocrinol Metab 14: 431-437, 2003. (Pubitemid 37392216)
25. Rockman HA, Koch WJ and Lefkowitz RJ: Seven-transmembrane-spanning receptors and heart function. Nature 415: 206-212, 2002. (Pubitemid 34059526)
26. Spiegel AM and Weinstein LS: Inherited diseases involving G proteins and G-protein-coupled receptors. Annu Rev Med 55: 27-39, 2004. (Pubitemid 38316714)
27. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005. (Pubitemid 40558990)
28. Krapivinsky G, Krapivinsky L, Wickman K and Clapham DE: G beta gamma binds directly to the G-protein-gated K+ channel, IKACh. J Biol Chem 270: 29059-29062, 1995. (Pubitemid 3016881)
29. Wilkie TM, Gilbert DJ, Olsen AS, Chen XN, Amatruda TT, Korenberg JR, Trask BJ, de Jong P, Reed RR, Simon MI: Evolution of the mammalian G protein alpha subunit multigene family. Nat Genet 1: 85-91, 1992.
30. Tan CM, Brady AE, Nickols HH, Wang Q and Limbird LE: Membrane trafficking of G-protein-coupled receptors. Annu Rev Pharmacol Toxicol 44: 559-609, 2004.
31. von Zastrow M: Mechanisms regulating membrane trafficking of G-protein-coupled receptors in the endocytic pathway. Life Sci 74: 217-224, 2003.
32. Tsao PI and von Zastrow M: Diversity and specificity in the regulated endocytic membrane trafficking of G-protein-coupled receptors. Pharmacol Ther 89: 139-147, 2001. (Pubitemid 32333037)
33. Offermanns S: G-Proteins as transducers in transmembrane signalling. Prog Biophys Mol Biol 83: 101-130, 2003.
34. Kopperud R, Krakstad C, Selheim F and Doskeland SO: cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett 546: 121-126, 2003. (Pubitemid 36782292)
35. Bos JL, de Rooij J and Reedquist KA: Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol 2: 369-377, 2001. (Pubitemid 33674049)
36. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ and Bone RF: Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48: 909-912, 2005. (Pubitemid 40270436)
37. Hamm HE: The many faces of G-protein signaling. J Biol Chem 273: 669-672, 1998.
38. Kaslow HR and Burns DL: Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J 6: 2684-2690, 1992.
39. Fraser CC: G-Protein-coupled receptor connectivity to NF-kappaB in inflammation and cancer. Int Rev Immunol 27: 320-350, 2008.
40. Boss V, Wang X, Koppelman LF, Xu K and Murphy TJ: Histamine induces nuclear factor of activated T-cell-mediated transcription and cyclosporin A-sensitive interleukin-8 mRNA expression in human umbilical vein endothelial cells. Mol Pharmacol 54: 264-272, 1998. (Pubitemid 28368815)
41. Abbott KL, Loss JR, 2nd, Robida AM and Murphy TJ: Evidence that G alpha(q)-coupled receptor-induced interleukin-6 mRNA in vascular smooth muscle cells involves the nuclear factor of activated T-cells. Mol Pharmacol 58: 946-953, 2000.
42. Macian F, Garcia-Rodriguez C and Rao A: Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J 19: 4783-4795, 2000.
43. Masuda ES, Imamura R, Amasaki Y, Arai K and Arai N: Signalling into the T-cell nucleus: NFAT regulation. Cell Signal 10: 599-611, 1998. (Pubitemid 28448460)
44. Liu S, Murph M, Panupinthu N and Mills GB: ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8: 3695-3701, 2009.
45. Dhanasekaran N and Dermott JM: Signaling by the G12 class of G proteins. Cell Signal 8: 235-245, 1996.
46. Radhika V and Dhanasekaran N: Transforming G proteins. Oncogene 20: 1607-1614, 2001. (Pubitemid 32336849)
47. Bian D, Mahanivong C, Yu J, Frisch SM, Pan ZK, Ye RD and Huang S: The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. Oncogene 25: 2234-2244, 2006.
48. Kaplan DD, Meigs TE and Casey PJ: Distinct regions of the Cadherin cytoplasmic domain are essential for functional interaction with G alpha 12 and beta-catenin. J Biol Chem 276: 44037-44043, 2001.
49. Meigs TE, Fields TA, McKee DD and Casey PJ: Interaction of G alpha 12 and G alpha 13 with the cytoplasmic domain of Cadherin provides a mechanism for beta-catenin release. Proc Natl Acad Sci USA 98: 519-524, 2001. (Pubitemid 32105074)
50. Bockaert J, Dumuis A, Fagni L and Marin P: GPCR-GIP networks: A first step in the discovery of new therapeutic drugs? Curr Opin Drug Discov Devel 7: 649-657, 2004. (Pubitemid 39329867)
51. Prossnitz ER: Novel roles for arrestins in the post-endocytic trafficking of G-protein-coupled receptors. Life Sci 75: 893-899, 2004.
52. Ferguson SS, Downey WE, 3rd, Colapietro AM, Barak LS, Menard L and Caron MG: Role of beta-arrestin in mediating agonist-promoted G-protein-coupled receptor internalization. Science 271: 363-366, 1996.
53. Reiter E and Lefkowitz RJ: GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17: 159-165, 2006.
54. Hunton DL, Barnes WG, Kim J, Ren XR, Violin JD, Reiter E, Milligan G, Patel DD and Lefkowitz RJ: Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of Chemotaxis. Mol Pharmacol 67: 1229-1236, 2005. (Pubitemid 40410423)
55. Witherow DS, Garrison TR, Miller WE and Lefkowitz RJ: β-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci USA 101: 8603-8607, 2004. (Pubitemid 38745817)
56. Penela P, Ribas C and Mayor F Jr.: Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 15: 973-981, 2003. (Pubitemid 37130155)
57. Qin Y, Verdegaal EM, Siderius M, Bebelman JP, Smit MJ, Leurs R, Willemze R, Tensen CP and Osanto S: Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res 24: 207-218, 2011.
58. Gao Y, Kitagawa K, Hiramatsu Y, Kikuchi H, Isobe T, Shimada M, Uchida C, Hattori T, Oda T, Nakayama K, Nakayama KI, Tanaka T, Konno H and Kitagawa M: Up-regulation of GPR48 induced by down-regulation of p27/Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res 66: 11623-11631, 2006. (Pubitemid 46094173)
59. Gugger M, White R, Song S, Waser B, Cescato R, Riviere P and Reubi JC: GPR87 is an overexpressed G-protein-coupled receptor in squamous cell carcinoma of the lung. Dis Markers 24: 41-50, 2008. (Pubitemid 350174569)
60. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T and Sakamoto M: G-Protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol 173: 835-843, 2008.
61. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M and Hirohashi S: Overexpression of orphan G-protein-coupled receptor, GPR49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 37: 528-533, 2003. (Pubitemid 36258773)
62. Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J, Nikolich K, Urfer R and Foehr ED: GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 24: 1673-1682, 2005. (Pubitemid 40461124)
63. Van Schoore G, Mendive F, Pochet R and Vassart G: Expression pattern of the orphan receptor Lgr4/Gpr48 gene in the mouse. Histochem Cell Biol 124: 35-50, 2005. (Pubitemid 41253161)
64. Mazerbourg S, Bouley DM, Sudo S, Klein CA, Zhang JV, Kawamura K, Goodrich LV, Rayburn H, Tessier-Lavigne M and Hsueh AJ: Leucine-rich repeat-containing, G-protein-coupled receptor 4 null mice exhibit intrauterine growth retardation associated with embryonic and perinatal lethality. Mol Endocrinol 18: 2241-2254, 2004. (Pubitemid 39215253)
65. Carmon KS, Gong X, Lin Q, Thomas A and Liu Q: R-Spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc Natl Acad Sci USA 108: 11452-11457, 2011.
66. de Lau W, Barker N, Low TY, Koo BK, Li VS, Teunissen H, Kujala P, Haegebarth A, Peters PJ, van de Wetering M, Stange DE, van Es J, Guardavaccaro D, Schasfoort RB, Mohri Y, Nishimori K, Mohammed S, Heck AJ and Clevers H: Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476: 293-297, 2011.
67. Mustata RC, Van Loy T, Lefort A, Libert F, Strollo S, Vassart G and Garcia MI: Lgr4 is required for Paneth cell differentiation and maintenance of intestinal stem cells ex vivo. EMBO Rep 12: 558-564, 2011.
68. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP and Rieber EP: D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun 322: 239-249, 2004. (Pubitemid 39093861)
69. Weng J, Wang J, Hu X, Wang F, Ittmann M and Liu M: PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer 118: 1471-1480, 2006.
70. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J and Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366: 575-580, 1993. (Pubitemid 24035999)
71. Mihai R, Stevens J, McKinney C and Ibrahim NB: Expression of the calcium receptor in human breast cancer-a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol 32: 511-515, 2006.
72. Manning AT, O'Brien N and Kerin MJ: Roles for the calcium sensing receptor in primary and metastatic cancer. Eur J Surg Oncol 32: 693-697, 2006. (Pubitemid 44276002)
73. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM and Sabo E: Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12: 6359-6366, 2006. (Pubitemid 44799705)
74. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M and Picard D: Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28: 523-532, 2009.
75. Xie F, Liu H, Zhu YH, Qin YR, Dai Y, Zeng T, Chen L, Nie C, Tang H, Li Y, Fu L and Guan XY: Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma. BMC Cancer 11: 86, 2011.
76. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S and Praia RL: Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951-961, 2000.
77. Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591, 2003. (Pubitemid 37328830)
78. Rivera-Lopez CM, Tucker AL and Lynch KR: Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11: 301-310, 2008.
79. Jonkers J and Moolenaar WH: Mammary tumorigenesis through LPA receptor signaling. Cancer Cell 15: 457-459, 2009.
80. Lin ME, Herr DR and Chun J: Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91: 130-138, 2010.
81. Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R, Sanavio F, Aglietta M, Ghigo D, Rola-Pleszczynski MR: Platelet-activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 96: 940-952, 1995.
82. Montrucchio G, Lupia E, Battaglia E, Del Sorbo L, Boccellino M, Biancone L, Emanuelli G and Camussi G: Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. Arterioscler Thromb Vasc Biol 20: 80-88, 2000. (Pubitemid 30048349)
83. Caunt M, Huang YQ, Brooks PC and Karpatkin S: Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost 1: 2097-2102, 2003.
84. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H and Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17: 4015-4023, 1997. (Pubitemid 27281877)
85. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
86. Moore BB, Keane MP, Addison CL, Arenberg DA and Strieter RM: CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Investig Med 46: 113-120, 1998. (Pubitemid 128456248)
87. Mishra KP, Ganju L, Sairam M, Banerjee PK and Sawhney RC: A review of high throughput technology for the screening of natural products. Biomed Pharmacother 62: 94-98, 2008. (Pubitemid 351215811)
88. Greasley PJ and Jansen FP: G-Protein-coupled receptor screening technologies. Drug Discovery Today: Technologies 2: 163-170, 2005. (Pubitemid 40946324)
89. Kallal L and Benovic JL: Using green fluorescent proteins to study G-Protein-coupled receptor localization and trafficking. Trends Pharmacol Sci 21: 175-180, 2000. (Pubitemid 30243199)
90. Milligan G: High-content assays for ligand regulation of G-Protein-coupled receptors. Drug Discov Today 8: 579-585, 2003.
91. Barak LS, Ferguson SS, Zhang J, Martenson C, Meyer T and Caron MG: Internal trafficking and surface mobility of a functionally intact beta2-adrenergic receptor-green fluorescent protein conjugate. Mol Pharmacol 51: 177-184, 1997. (Pubitemid 27074137)
92. Ambrosio M, Zurn A and Lohse MJ: Sensing G-protein-coupled receptor activation. Neuropharmacology 60: 45-51, 2011.
93. Vilardaga JP, Bunemann M, Krasel C, Castro M and Lohse MJ: Measurement of the millisecond activation switch of G-protein-coupled receptors in living cells. Nat Biotechnol 21: 807-812, 2003. (Pubitemid 36791401)
94. Vidi PA, Ejendal KF, Przybyla JA and Watts VJ: Fluorescent protein complementation assays: new tools to study G-protein-coupled receptor oligomerization and GPCR-mediated signaling. Mol Cell Endocrinol 331: 185-193, 2011.
95. Przybyla JA and Watts VJ: Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 332: 710-719, 2010.
96. Vidi PA, Chen J, Irudayaraj JM and Watts VJ: Adenosine A(2A) receptors assemble into higher-order oligomers at the plasma membrane. FEBS Lett 582: 3985-3990, 2008.
97. Mishina YM, Wilson CJ, Bruett L, Smith JJ, Stoop-Myer C, Jong S, Amaral LP, Pedersen R, Lyman SK, Myer VE, Kreider BL and Thompson CM: Multiplex GPCR assay in reverse transfection cell microarrays. J Biomol Screen 9: 196-207, 2004.
98. Fang Y, Frutos AG and Lahiri J: G-Protein-coupled receptor microarrays. Chem Biochem 3: 987-991, 2002. (Pubitemid 35177751)
99. Fang Y, Lahiri J and Picard L: G-Protein-coupled receptor microarrays for drug discovery. Drug Discov Today 8: 755-761, 2003. (Pubitemid 37011247)
100. Ross DA, Lee S, Reiser V, Xue J, Alves K, Vaidya S, Kreamer A, Mull R, Hudak E, Hare T, Detmers PA, Lingham R, Ferrer M, Strulovici B and Santini F: Multiplexed assays by high-content imaging for assessment of GPCR activity. J Biomol Screen 13: 449-455, 2008. (Pubitemid 351905074)
101. Kitano H: Computational systems biology. Nature 420: 206-210, 2002.
102. Kirschner MW: The meaning of systems biology. Cell 121: 503-504, 2005.
103. Aderem A: Systems biology: its practice and challenges. Cell 121: 511-513, 2005.
104. Friboulet A and Thomas D: Systems biology an interdisciplinary approach. Biosens Bioelectron 20: 2404-2407, 2005.
105. Kim TK: Chemical genomics and medicinal systems biology: chemical control of genomic networks in human systems biology for innovative medicine. J Biochem Mol Biol 37: 53-58, 2004.
106. Gardy JL, Lynn DJ, Brinkman FS and Hancock RE: Enabling a systems biology approach to immunology: focus on innate immunity. Trends Immunol 30: 249-262, 2009.
107. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjoblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio LA, Wang TL, Markowitz SD, Parmigiani G, Kinzler KW, Vogelstein B and Velculescu VE: Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105: 16224-16229, 2008.
108. Gonzalez A, Lopez B, Beaumont J, Ravassa S, Arias T, Hermida N, Zudaire A and Diez J: Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research. Rev Esp Cardiol 62: 305-313, 2009.
109. Lockhart DJ and Winzeler EA: Genomics, gene expression and DNA arrays. Nature 405: 827-836, 2000. (Pubitemid 30407861)
110. Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, Snijders A, Albertson DG, Pinkel D, Marra MA, Ling V, MacAulay C and Lam WL: A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 36: 299-303, 2004. (Pubitemid 38282757)
111. Pioch D, Schweder T and Jurgen B: Novel developments for improved detection of specific mRNAs by DNA chips. Appl Microbiol Biotechnol 80: 953-963, 2008.
112. Ye P, Mariniello B, Mantero F, Shibata H and Rainey WE: G-Protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 195: 39-48, 2007. (Pubitemid 350055997)
113. Midorikawa Y, Makuuchi M, Tang W and Aburatani H: Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol 13: 1487-1492, 2007. (Pubitemid 46672654)
114. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T and Aburatani H: Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62: 233-240, 2002. (Pubitemid 34074010)
115. Mohr S, Leikauf GD, Keith G and Rihn BH: Microarrays as cancer keys: an array of possibilities. J Clin Oncol 20: 3165-3175, 2002. (Pubitemid 34791107)
116. Frolov AE, Godwin AK and Favorova OO: Differential gene expression analysis by DNA microarrays technology and its application in molecular oncology. Mol Biol (Mosk) 37: 573-584, 2003.
117. Riedmaier I, Becker C, Pfaffl MW and Meyer HH: The use of omic technologies for biomarker development to trace functions of anabolic agents. J Chromatogr A 1216: 8192-8199, 2009.
118. Maurel B, Le Digarcher A, Dantec C and Journot L: Genome-wide profiling of G- protein-coupled receptors in cerebellar granule neurons using high-throughput, real-time PCR. BMC genomics 12: 241, 2011.
119. Atwood BK, Lopez J, Wager-Miller J, Mackie K and Straiker A: Expression of G-protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC genomics 12: 14, 2011.
120. Fredriksson R and Schioth HB: The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 67: 1414-1425, 2005. (Pubitemid 40594140)
121. Ostrom RS and Insel PA: The evolving role of lipid rafts and caveolae in G-protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 143: 235-245, 2004. (Pubitemid 39315143)
122. Wodicka L, Dong H, Mittmann M, Ho MH and Lockhart DJ: Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 15: 1359-1367, 1997. (Pubitemid 28022729)
123. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H and Brown EL: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14: 1675-1680, 1996. (Pubitemid 26414810)
124. Hansen A, Chen Y, Inman JM, Phan QN, Qi ZQ, Xiang CC, Palkovits M, Cherman N, Kuznetsov SA and Robey PG: Sensitive and specific method for detecting G-protein-coupled receptor mRNAs. Nature Methods 4: 35-37, 2006.
125. Hakak Y, Shrestha D, Goegel MC, Behan DP and Chalmers DT: Global analysis of G-protein-coupled receptor signaling in human tissues. FEBS letters 550: 11-17, 2003. (Pubitemid 37281349)
126. Regard JB, Sato IT and Coughlin SR: Anatomical profiling of G-protein-coupled receptor expression. Cell 135: 561-571, 2008.
127. Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez JC, Yan JX, Gooley AA, Hughes G, Humphery-Smith I, Williams KL and Hochstrasser DF: From proteins to proteomes: large-scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 14: 61-65, 1996.
128. Nice EC, Rothacker J, Weinstock J, Lim L and Catimel B: Use of multidimensional separation protocols for the purification of trace components in complex biological samples for proteomics analysis. J Chromatogr A 1168: 190-210; discussion 189, 2007.
129. Liu R, Wang K, Yuan K, Wei Y and Huang C: Integrative oncoproteomics strategies for anticancer drug discovery. Expert Rev Proteomics 7: 411-429, 2010.
130. Pluder F, Mori K and Beck-Sickinger AG: Proteome analysis to study signal transduction of G-protein-coupled receptors. Pharmacol Ther 112: 1-11, 2006. (Pubitemid 44301482)
131. Kamonchanok S, Balog CI, van der Does AM, Booth R, de Grip WJ, Deelder AM, Bakker RA, Leurs R and Hensbergen PJ: GPCR proteomics: mass spectrometric and functional analysis of histamine H1 receptor after baculovirus-driven and in vitro cell-free expression. J Proteome Res 7: 621-629, 2008. (Pubitemid 351294024)
132. Becamel C, Alonso G, Galeotti N, Demey E, Jouin P, Ullmer C, Dumuis A, Bockaert J and Marin P: Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. EMBO J 21: 2332-2342, 2002. (Pubitemid 34546706)
133. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, Yates JR, 3rd and Lefkowitz RJ: Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 104: 12011-12016, 2007. (Pubitemid 47185621)
134. Pawson T and Scott JD: Signaling through scaffold, anchoring, and adaptor proteins. Science 278: 2075-2080, 1997. (Pubitemid 28028310)
135. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P and Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127: 635-648, 2006. (Pubitemid 44647421)
136. Macek B, Mann M and Olsen JV: Global and site-specific quantitative phosphoproteomics: principles and applications. Annu Rev Pharmacol Toxicol 49: 199-221, 2009.
137. Christensen GL, Kelstrup CD, Lyngso C, Sarwar U, Bogebo R, Sheikh SP, Gammeltoft S, Olsen JV and Hansen JL: Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9: 1540-1553, 2010.
138. Gonzalez-Angulo AM, Hennessy BT and Mills GB: Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 28: 2777-2783, 2010.
139. Wheelock CE, Wheelock M, Kawashima S, Diez D, Kanehisa M, van Erk M, Kleemann R, Haeggstr m JZ and Goto S: Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol BioSyst 5: 588-602, 2009.
140. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC and Schall TJ: CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumorassociated vasculature. Proc Natl Acad Sci USA 104: 15735-15740, 2007. (Pubitemid 350035369)
141. Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G and Camussi G: PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 157: 1713-1725, 2000.
142. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and Bar-Shavit R: Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4: 909-914, 1998. (Pubitemid 28364029)
143. Darmoul D, Gratio V, Devaud H, Lehy T and Laburthe M: Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 162: 1503-1513, 2003. (Pubitemid 36512832)
144. Ahuja SK and Murphy PM: The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 271: 20545-20550, 1996.
145. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD and Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97: 2792-2802, 1996. (Pubitemid 26197092)
146. Miller LJ, Kurtzman SH, Wang Y, Anderson KH, Lindquist RR and Kreutzer DL: Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 18: 77-81, 1998. (Pubitemid 28174688)
147. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA and Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6: 2104-2119, 2000. (Pubitemid 30305111)
148. Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735, 2008.
149. Loukinova E, Dong G, Enamorado-Ayalya I, Thomas GR, Chen Z, Schreiber H and Van Waes C: Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19: 3477-3486, 2000. (Pubitemid 30487445)
150. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S and Karpatkin S: Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 66: 4125-4132, 2006.
151. Conti I and Rollins BJ: CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 14: 149-154, 2004. (Pubitemid 38586739)
152. Craig MJ and Loberg RD: CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev 25: 611-619, 2006. (Pubitemid 46071867)
153. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, Fujii N and Imamura M: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6: 3530-3535, 2000.
154. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M and Yamamoto N: Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 60: 273-276, 2006. (Pubitemid 44223937)